Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients

Jun Li, Zhao Wu, Gui-Qiang Wang, Hong Zhao, Jun Li, Zhao Wu, Gui-Qiang Wang, Hong Zhao

Abstract

Background: Hepatitis B core-related antigen (HBcrAg) is a promising disease-monitoring marker for chronic hepatitis B (CHB). We investigated correlations between HBcrAg with antiviral efficacy and virological and histological variables.

Methods: One hundred and forty-five CHB patients from the mainland of China between August 2013 and September 2016 who underwent liver biopsy received entecavir therapy and had paired liver biopsy at 78 weeks. We analyzed correlations between HBcrAg and virological and histological variables in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients. We also explored the predictors of HBeAg loss after 78 weeks of antiviral therapy. Pearson correlation analysis and logistic forward stepwise regression were the main statistic methods.

Results: HBeAg-positive patients (n = 93) had higher baseline HBcrAg (median 7.4 vs. 5.3 log10 U/mL P < 0.001) and greater HBcrAg declines (median 1.6 vs. 0.9 log10 U/mL P = 0.007) than HBeAg-negative patients after 78 weeks of therapy. At baseline, HBcrAg correlated with hepatitis B virus (HBV) DNA in both HBeAg-positive (r = 0.641, P < 0.001) and -negative patients (r = 0.616, P < 0.001), with hepatitis B surface antigen (HBsAg) in HBeAg-positive patients (r = 0.495, P < 0.001), but not with anti-hepatitis B virus core antibody (anti-HBc). Weak correlations existed between HBcrAg, histology activity index (HAI; r = 0.232, P = 0.025), and Ishak fibrosis score (r = -0.292, P = 0.005) in HBeAg-positive patients. At 78 weeks, significant correlations existed only between HBcrAg and anti-HBc in HBeAg-positive (r = -0.263, P = 0.014) and HBeAg-negative patients (r = -0.291, P = 0.045). Decreased HBcrAg significantly correlated with reduced HBV DNA (r = 0.366, P = 0.001; r = 0.626, P < 0.001) and HBsAg (r = 0.526, P = 0.001; r = 0.289, P = 0.044) in HBeAg-positive and -negative patients, respectively, and with reduced HAI in HBeAg-positive patients (r = 0.329, P = 0.001). Patients with HBeAg loss (n = 29) showed a larger reduction in HBcrAg than those without (median 2.3 vs. 1.3 log10 U/mL, P = 0.001). In multivariate analysis, decreased HBcrAg was an independent predictor of HBeAg loss (P = 0.005).

Conclusions: HBcrAg reflects viral replication and protein production. Decreased HBcrAg could predict HBeAg loss after antiviral therapy.

Trial registration: Clinical Trials.gov: NCT01962155; https://www.clinicaltrials.gov/ct2/show/NCT01962155?term=NCT01962155&draw=2&rank=1.

Conflict of interest statement

None.

Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

References

    1. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, et al. . Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3:383–403. doi: 10.1016/S2468-1253(18)30056-6.
    1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67:370–398. doi: 10.1016/j.jhep.2017.03.021.
    1. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HYL, Chen CJ, et al. . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10:1–98. doi: 10.1007/s12072-015-9675-4.
    1. Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol 2019; 4:883–892. doi: 10.1016/S2468-1253(19)30190-6.
    1. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015; 64:1972–1984. doi: 10.1136/gutjnl-2015-309809.
    1. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res 2014; 44: Suppl S1: 1–58. doi: 10.1111/hepr.12272.
    1. Chuaypen N, Posuwan N, Chittmittraprap S, Hirankarn N, Treeprasertsuk S, Tanaka Y, et al. . Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin Microbiol Infect 2018; 24:306.e7–306.e13. doi: 10.1016/j.cmi.2017.07.016.
    1. Seto W-K, Wong DK, Chan TS, Hwang Y-Y, Fung J, Liu KS, et al. . Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy. Am J Gastroenterol 2016; 111:1788–1795. doi: 10.1038/ajg.2016.436.
    1. Tseng T-C, Liu C-J, Hsu C-Y, Hong C-M, Su T-H, Yang W-T, et al. . High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology 2019; 157:1518–1529.e3. doi: 10.1053/j.gastro.2019.08.028.
    1. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, et al. . HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30:1461–1470. doi: 10.1111/j.1478-3231.2010.02344.x.
    1. Inoue T, Tanaka Y. The role of hepatitis B core-related antigen. Genes (Basel) 2019; 10:357.doi: 10.3390/genes10050357.
    1. Mak L-Y, Wong DK-H, Cheung K-S, Seto W-K, Lai C-L, Yuen M-F, et al. . Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmcol Ther 2018; 47:43–54. doi: 10.1111/apt.14376.
    1. Wang M-L, Deng R, Chen E-Q, Tao C-M, Liao J, Zhou T-Y, et al. . Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy. Clin Res Hepatol Gastroenterol 2019; 43:301–309. doi: 10.1016/j.clinre.2018.10.020.
    1. Wang L, Cao X, Wang Z, Gao Y, Deng J, Liu X, et al. . Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. J Clin Microbiol 2019; 57:e01303–e01318. doi: 10.1128/JCM.01303-18.
    1. Wong DK-H, Seto W-K, Cheung K-S, Chong C-K, Huang F-Y, Fung J, et al. . Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017; 37:995–1001. doi: 10.1111/liv.13346.
    1. Chang X-J, Sun C, Chen Y, Li X-D, Yu Z-J, Dong Z, et al. . On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol 2019; 25:4764–4778. doi: 10.3748/wjg.v25.i32.4764.
    1. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67:1560–1599. doi: 10.1002/hep.29800.
    1. Wang B, Carey I, Bruce M, Montague S, Dusheiko G, Agarwal K. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. J Viral Hepat 2018; 25:886–893. doi: 10.1111/jvh.12889.
    1. Sonneveld MJ, van Oord GW, van Campenhout MJ, De Man RA, Janssen HLA, de Knegt RJ, et al. . Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Viral Hepat 2019; 26:828–834. doi: 10.1111/jvh.13097.
    1. Jia W, Song L-W, Fang Y-Q, Wu X-F, Liu D-Y, Xu C, et al. . Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine (Baltimore) 2014; 93:e322.doi: 10.1097/MD.0000000000000322.
    1. Li A, Yuan Q, Huang Z, Fan J, Guo R, Lou B, et al. . Novel double-antigen sandwich immunoassay for human hepatitis B core antibody. Clin Vaccine Immunol 2010; 17:464–469. doi: 10.1128/CVI.00457-09.
    1. Tanaka E, Matsumoto A, Suzuki F, Kobayashi M, Mizokami M, Tanaka Y, et al. . Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int 2006; 26:90–96. doi: 10.1111/j.1478-3231.2005.01200.x.
    1. Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, et al. . Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37:661–666. doi: 10.1111/j.1872-034X.2007.00094.x.
    1. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. . Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696–699. doi: 10.1016/0168-8278(95)80226-6.
    1. Loggi E, Vukotic R, Conti F, Grandini E, Gitto S, Cursaro C, et al. . Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019; 26:568–575. doi: 10.1111/jvh.13054.
    1. Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, et al. . Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015; 21:606.e1–606.e10. doi: 10.1016/j.cmi.2015.02.010.
    1. Testoni B, Lebosse F, Scholtes C, Berby F, Miaglia C, Subic M, et al. . Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019; 70:615–625. doi: 10.1016/j.jhep.2018.11.030.
    1. Rokuhara A, Sun X, Tanaka E, Kimura T, Matsumoto A, Yao D, et al. . Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. J Gastroenterol Hepatol 2005; 20:1726–1730. doi: 10.1111/j.1440-1746.2005.04087.x.
    1. Wong DK-H, Tanaka Y, Lai C-L, Mizokami M, Fung J, Yuen M-F, et al. . Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007; 45:3942–3947. doi: 10.1128/JCM.00366-07.
    1. Lam Y-F, Seto W-K, Wong D, Cheung K-S, Fung J, Mak L-Y, et al. . Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol 2017; 8:e125.doi: 10.1038/ctg.2017.51.
    1. Kimura T, Ohno N, Terada N, Rokuhara A, Matsumoto A, Yagi S, et al. . Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 2005; 280:21713–21719. doi: 10.1074/jbc.M501564200.
    1. Chen E-Q, Wang M-L, Tao Y-C, Wu D-B, Liao J, He M, et al. . Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat 2019; 26:586–595. doi: 10.1111/jvh.13061.
    1. Cornberg M, Wong VW-S, Locarnini S, Brunetto M, Janssen HLA, Chan HL-Y, et al. . The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66:398–411. doi: 10.1016/j.jhep.2016.08.009.
    1. Song L-W, Liu P-G, Liu C-J, Zhang T-Y, Cheng X-D, Wu H-L, et al. . Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. Clin Microbiol Infect 2015; 21:197–203. doi: 10.1016/j.cmi.2014.10.002.
    1. Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, et al. . Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. Antivir Ther 2018; 24:105–115. doi: 10.3851/IMP3280.
    1. Song G, Yang R, Rao H, Feng B, Ma H, Jin Q, et al. . Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. J Med Virol 2017; 89:463–468. doi: 10.1002/jmv.24657.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren